Seyed Arsham Mirzaei
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Seyed Arsham Mirzaei has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Ali Noursina
School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
3 shared publications - Farzad Safari
School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
3 shared publications - Hanieh Rouzbahani
School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
3 shared publications - Elena Malekpour
School of Health, Isfahan University of Medical Sciences, Isfahan, Iran
2 shared publications - Faraz Golafshan
School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
2 shared publications - Mohammad Reza Chitsazi
Faculty of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran
2 shared publications
Latest Publications
- 27 December 2025
- Published by Springer Nature in Probiotics and Antimicrobial Proteins
- Vol. 18 (4) , 5363-5379
Functional Proteins of Akkermansia Muciniphila: Impacts on Host Health and Metabolism
- 27 December 2025
- Published by Springer Nature in Probiotics and Antimicrobial Proteins
- Vol. 18 (4) , 5363-5379
Functional Proteins of Akkermansia Muciniphila: Impacts on Host Health and Metabolism
- Open Access
- 8 October 2025
- Published by Springer Nature in BMC Gastroenterology
- Vol. 25 (1) , 1-25
The pathobiont role of Akkermansia muciniphila in colorectal cancer: a systematic review
Colorectal cancer (CRC) is the second leading cause of cancer-related mortality worldwide. Emerging evidence highlights the gut microbiota, particularly Akkermansia muciniphila, as a key modulator in CRC pathogenesis. While often regarded as a beneficial commensal, its role in CRC appears complex and potentially dualistic. This systematic review aims to comprehensively analyze the context-dependent role of A. muciniphila in CRC, evaluating its potential as a pathobiont. We systematically reviewed human, animal, in vitro, and ex vivo studies on associations between A. muciniphila and CRC risk or outcomes. Database searches identified 34 eligible studies. Study quality was assessed using the GRADE criteria. From 244 initial records, 34 studies met the inclusion criteria. Findings reveal a stark dichotomy: non-viable forms of A. muciniphila—including pasteurized bacteria, outer membrane vesicles (OMVs), and purified proteins (e.g., Amuc_1100, Amuc_2172, Amuc_1434*)—consistently demonstrate anti-tumorigenic effects. These components enhance anti-tumor immunity by activating CD8 + T cells, promoting M1-like macrophage polarization via TLR2/NLRP3 signaling, and sensitizing tumors to chemotherapy and anti-PD-1 immunotherapy. Conversely, administration of live A. muciniphila can exert pro-tumorigenic effects, particularly in inflammatory contexts (e.g., colitis-associated CRC) or post-antibiotic settings, likely due to excessive mucin degradation and gut barrier disruption. Host factors such as obesity, sex, genetics, and microbial interactions further modulate its impact. A. muciniphila functions as a pathobiont in CRC, with its role critically dependent on its biological state and host context. Therapeutic strategies should shift from live probiotics to targeted postbiotic applications of its beneficial components to maximize efficacy and safety.
- 8 October 2025
- Published by Springer Nature in BMC Gastroenterology
- Vol. 25 (1) , 1-25
Open AccessThe pathobiont role of Akkermansia muciniphila in colorectal cancer: a systematic review
Colorectal cancer (CRC) is the second leading cause of cancer-related mortality worldwide. Emerging evidence highlights the gut microbiota, particularly Akkermansia muciniphila, as a key modulator in CRC pathogenesis. While often regarded as a beneficial commensal, its role in CRC appears complex and potentially dualistic. This systematic review aims to comprehensively analyze the context-dependent role of A. muciniphila in CRC, evaluating its potential as a pathobiont. We systematically reviewed human, animal, in vitro, and ex vivo studies on associations between A. muciniphila and CRC risk or outcomes. Database searches identified 34 eligible studies. Study quality was assessed using the GRADE criteria. From 244 initial records, 34 studies met the inclusion criteria. Findings reveal a stark dichotomy: non-viable forms of A. muciniphila—including pasteurized bacteria, outer membrane vesicles (OMVs), and purified proteins (e.g., Amuc_1100, Amuc_2172, Amuc_1434*)—consistently demonstrate anti-tumorigenic effects. These components enhance anti-tumor immunity by activating CD8 + T cells, promoting M1-like macrophage polarization via TLR2/NLRP3 signaling, and sensitizing tumors to chemotherapy and anti-PD-1 immunotherapy. Conversely, administration of live A. muciniphila can exert pro-tumorigenic effects, particularly in inflammatory contexts (e.g., colitis-associated CRC) or post-antibiotic settings, likely due to excessive mucin degradation and gut barrier disruption. Host factors such as obesity, sex, genetics, and microbial interactions further modulate its impact. A. muciniphila functions as a pathobiont in CRC, with its role critically dependent on its biological state and host context. Therapeutic strategies should shift from live probiotics to targeted postbiotic applications of its beneficial components to maximize efficacy and safety.